Sarepta Therapeutics, Inc. (SRPT)
17.85
-0.36
(-1.98%)
USD |
NASDAQ |
Oct 09, 16:00
17.86
0.00 (0.00%)
Pre-Market: 20:00
Sarepta Therapeutics Cash from Operations (Quarterly) : 197.07M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 197.07M |
| March 31, 2026 | -202.68M |
| December 31, 2025 | 126.93M |
| September 30, 2025 | -27.37M |
| June 30, 2025 | 261.34M |
| March 31, 2025 | -583.44M |
| December 31, 2024 | 92.05M |
| September 30, 2024 | -70.70M |
| June 30, 2024 | 14.94M |
| March 31, 2024 | -242.08M |
| December 31, 2023 | -54.66M |
| September 30, 2023 | -114.71M |
| June 30, 2023 | -122.23M |
| March 31, 2023 | -209.40M |
| December 31, 2022 | -92.39M |
| September 30, 2022 | -64.96M |
| June 30, 2022 | -66.82M |
| March 31, 2022 | -101.18M |
| December 31, 2021 | -29.33M |
| September 30, 2021 | -124.33M |
| June 30, 2021 | -109.15M |
| March 31, 2021 | -180.37M |
| December 31, 2020 | -174.54M |
| September 30, 2020 | -238.19M |
| June 30, 2020 | -107.60M |
| Date | Value |
|---|---|
| March 31, 2020 | 627.79M |
| December 31, 2019 | -168.13M |
| September 30, 2019 | -67.43M |
| June 30, 2019 | -79.00M |
| March 31, 2019 | -146.23M |
| December 31, 2018 | -122.42M |
| September 30, 2018 | -113.32M |
| June 30, 2018 | -117.25M |
| March 31, 2018 | -35.67M |
| December 31, 2017 | -31.06M |
| September 30, 2017 | -57.90M |
| June 30, 2017 | -85.15M |
| March 31, 2017 | -57.89M |
| December 31, 2016 | -81.23M |
| September 30, 2016 | -60.62M |
| June 30, 2016 | -43.28M |
| March 31, 2016 | -60.69M |
| December 31, 2015 | -31.27M |
| September 30, 2015 | -46.31M |
| June 30, 2015 | -28.53M |
| March 31, 2015 | -43.35M |
| December 31, 2014 | -25.45M |
| September 30, 2014 | -35.32M |
| June 30, 2014 | -39.50M |
| March 31, 2014 | -28.26M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Moderna, Inc. | -526.00M |
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Beam Therapeutics, Inc. | -66.10M |
| Twist Bioscience Corp. | 1.115M |
| ImmunityBio, Inc. | -66.49M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -93.37M |
| Free Cash Flow | 58.34M |
| Free Cash Flow Per Share (Quarterly) | 1.864 |
| Free Cash Flow to Equity (Quarterly) | 187.33M |
| Free Cash Flow to Firm (Quarterly) | 256.65M |
| Free Cash Flow Yield | 3.02% |